With appropriate management strategies, most patients can continue their GLP-1 treatment whilst maintaining comfortable bowel function
Cagrilintide is a 39amino-acid peptide with structural modifications (including an N-terminal fatty diacid chain) designed to improve stability and reduce fibril formation compared with native amylin
PMID: 8118430 Collins S, Surwit RS
adult obesity rate, calculated as having a BMI of 30 or higher, has gradually declined to 37% in 2025, dropping from a record high of 39.9% in 2022, according to a survey by the Gallup National Health and Well-Being Index released on Oct
[1] [2] The timing of side effects is closely linked to the drug's pharmacokinetic profile
Its a fair confusion, and the short answer is they operate on completely different principles